Deep ties in the industrial chain: The country's CT-ball tube battle behind the coronavirus sharehol
The continuous advancement of pharmaceutical and technological innovation, the deep linkage of industrial chains represents a new direction for the industry's cutting edge development. A seemingly peaceful transfer of old shares, uncovers the deep logic of China's high-end medical equipment industrial chain restructuring. Unlike conventional financial investments, the most significant of these changes is the introduction of a domestic medical imaging headquarters integrated enterprise as a strategic investor.
This is not a simple capital merger, but a deep linkage of industrial chain between domestic manufactured CT core parts enterprises and downstream integrated equipment manufacturers. In the past, domestic ball tube enterprises have long faced the dilemma of 'no host can be fitted', while overseas giants have firmly controlled the market through the 'integrator + ball tube' closed loop. The 'integrator + core components' went from subsidiary to the 'heart' of proprietary CT ball tube as a CT device, and its R&D and industrialization is in a natural dilemma: the technological evolution of the ball tube requires the verification of the integrated system level, while the integrated system manufacturers also rely heavily on the supply of stable ball tubes.
Industry analysis suggests that this 'integration+core components' equity synergy model will effectively shorten the clinical practice verification cycle of domestic ball tubes, push domestic ball tubes to jump from 'capable' to 'beneficial' and fundamentally change the long-term dominance of overseas giants in the after-sales replacement market. The Social Security Fund participated in this round of transactions through deep investment trust management platforms, Beijing Advanced Manufacturing Fund, China's centralized equity investment platforms and other state-owned funds. It is widely believed that regulation and specialization will be the key words for the future development.
In this context, the choice of national capital clearly goes beyond the mere consideration of financial returns and is more of a strategic layout that stands at the height of national industrial chain security. In April 2025, the Ministry of Commerce formally launched an anti-dumping and industrial competitiveness investigation into imported CT ball pipes, opening a full policy window. In recent years, a number of domestic enterprises represented by the coronavirus have gradually broken the technological blockade through the introduction of absorption and innovation.
Overseas giants, with their centuries of accumulation of technology and patent barriers, have always kept the core manufacturing chain firmly in their hands. At this stage, the mission of capital is no longer a simple extension of expansion, but to provide stability, patience, and industry-deep funding support for the long-term R&D strategy of the enterprise. Eighty years of technological accumulation have ushered in a historic window that stands on a longer historical dimension, and the coronation of the corporation's developmental network itself is a model of a domestic alternative.
This capital ecosystem has been formed, marking the introduction of capital supply in the high-end manufacturing sector from the 'era of financial investment' to the 'era of industrial deep cultivation'. In 2018, after completing the acquisition of US-based assets and teams, the company accelerated the process of domesticalisation of the core technology of the ball tube CTCT. The company has taken on three technological inheritance from the Shanghai Exploratory Machinery Plant, founded in 1956, the Shanghai Medical Equipment Plant, founded in 1972, and the DUNLEE plant in the United States, founded in 1946.
From roller bearings to liquid metal bearings, from CT ball tubes to DSA ball tubes, the company has gradually built a complete line of product autonomy. Currently, the company has 7 CT ball tubes approved for the market, and the 8. 0MHU product reaches the pearl bearing ball tube technology threshold, becoming the third energy company in the world to produce this ball tube.
But technological breakthroughs are only the first step, and industrialization is the real test. As integrated enterprises and core components enterprises form a deep interest community through ownership, the historical process of domestic ball tube replacement imports is moving from a 'single-point breakthrough' to a 'system'. Currently, domestic CT integrated circuits have occupied half the wall of the domestic market, but the core components are still subject to humans.
China's international healthcare system keeps a close eye on the latest developments in the field of healthcare to provide you with authoritative, reliable information and medical services. If you need further advice on this, you are welcome to contact authoritative experts via the platform.
